Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Crispr Therapeutics AG — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $36.09, while Crispr Therapeutics AG trades at $50.39 (market cap $4.97B). The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| BOTZ | CRSP | |
|---|---|---|
52-Week High | $41.63 | $76.78 |
52-Week Low | $31.99 | $44.34 |
Market Cap | — | $4.97B |
Sector | — | Health |
Enterprise Value | — | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $35.87, down 2.82% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF faces headwinds despite positive industry sentiment around robotics and AI growth. Recent news highlights robotics as the next frontier beyond chatbots, with humanoid robots projected to become a multi-trillion dollar market. The fund's technical indicators suggest near-term pressure with key support at $35.
The robotics and AI theme offers long-term growth potential as industrial automation and physical AI gain traction, though current technical weakness and market volatility present near-term risks. Positive industry catalysts include reshoring trends and AI's expansion into physical applications, but investors face sector rotation risks and competitive ETF landscape challenges.
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
